BD stock slips despite Q1 FY26 beat (BDX:NYSE)

robot
Abstract generation in progress

BD (Becton, Dickinson and Company) stock traded lower in premarket despite reporting better-than-expected Q1 fiscal 2026 financials. The decline was attributed to its life sciences segment underperforming Wall Street estimates. The company, a MedTech firm, also had another announcement concurrently with its earnings report.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin